Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit

Drug Metabolism and Disposition

Volumn 25, Issue 8, 1997, Pages 921-926

  Leeds, Janet M ^a   Henry, Scott P ^b   Truong, Loanne ^b   Zutshi, Anup ^b   Levin, Arthur A ^b   Kornbrust, Doug ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION EXCHANGE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE DEFICIENCY; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RABBIT; RADIOACTIVITY; VITREOUS BODY;

ANIMALS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; CYTOMEGALOVIRUS RETINITIS; MODELS, CHEMICAL; RABBITS; RADIOCHEMISTRY; THIONUCLEOTIDES; VITREOUS BODY;

ANIMALIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; ORYCTOLAGUS CUNICULUS;

EID: 0030874388     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. E. Bayever, P. L. Iversen, M. R. Bishop, J. G. Sharp, H. K. Tewary, M. A. Arneson, S. J. Pirruccello, R. W. Ruddon, A. Kessinger, G. Zon, and J. O. Armitage: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase 1 trial. Antisense Res. Develop. 3, 383-390 (1993).
2. J. M. Glover, J. M. Leeds, T. G. K. Mant, D. Amin, D. L. Kisner, J. Zuckerman, A. A. Levin, and W. R. Shanahan: Phase 1 safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther., in press.
3. R. Zhang, J. Yan, H. Shahinian, G. Amin, Z. Lu, T. Liu, M. S. Saag, Z. Jiang, J. Temsamani, R. Martin, P. J. Schechter, S. Agrawal, and R. B. Diasio: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58, 45-53 (1995).
4. 3H-labeled oligonucleotides; I: comparison of a phosphodiester and phosphorothioate. Mol. Pharmacol. 45, 932-943 (1994).
5. S. Agrawal, J. Temsamani, and J. Y. Tang: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599 (1991).
6. N. M. Dean, and R. McKay: Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. 91, 11762-11766 (1994).
7. N. M. Dean, R. McKay, T. P. Condon, and C. F. Bennett: Inhibition of Protein Kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters *. J. Biol. Chem. 269, 16416-16424 (1994).
8. S. T. Crooke, and C. F. Bennett: Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 107-129 (1996).
9. R. Azad, V. B. Driver, K. Tanaka, R. M. Crooke, and K. P. Anderson: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37, 1945-1954 (1993).
10. K. P. Anderson, R. F. Azad, H. Zhang, J. Huffman, R. Miner, and W. L. Drew: Growth inhibition of clinical and drug-resistant isolates of human cytomegalovirus by the antisense phosphorothioate oligonucleotide ISIS 2922. Internal Report. Isis Pharmaceuticals, Carlsbad, CA (1996).
11. R. F. Azad, V. B. Brown-Driver, J. Buckheit, R. W. Jr., and K. P. Anderson: Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res. 28, 101-111 (1995).
12. 14C]-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190 (1993).
13. R. Zhang, R. B. Diasio, Z. Lu, T. Liu, Z. Jiang, W. M. Galbraith, and S. Agrawal: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (Gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49, 929-939 (1995).
14. Y. Saijo, L. Perlaky, H. Wang, and H. Busch: Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6, 243-249 (1994).
15. 14C] labeled oligonucleotides. J. Label. Comp. Radiopharm. 36, 15-31 (1995).
16. P. Tanswell and J. Koup: TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 514-520 (1993).
17. 14C]-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94 (1994).
18. S. T. Crooke, M. J. Graham, J. E. Zuckerman, D. Brooks, B. S. Conklin, L. L. Cummins, M. J. Greig, C. J. Guinosso, D. Kornbrust, M. Manoharan, H. M. Sasmor, T. Schleich, K. L. Tivel, and R. H. Griffey: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937 (1996).
19. 2O following intravitreal administration to dutch-belted rabbits. Proceedings of AAPS 12, S339 (1995).
20. D. R. Dolnak, D. Munguia, C. A. Wiley, E. De Clercq, G. L. Vergeron-Lynn, C. Boscher, J. D. Connor, C. Sherwood, E. Capparelli, R. Armani, and W. R. Freeman: Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. Invest. Ophthalmol. Vis. Sci. (Washington, DC) 33, 1557-1563 (1992).
21. M. P. Pang, R. V. Branchflower, A. T. Chang, G. A. Peyman, H. Blatt, and H. K. Minatoya: Half-life and vitreous clearance of trifluorothymidine after intravitreal injection in the rabbit eye. Can. J. Ophthalmol. 27, 6-9 (1992).
22. P. Berthe, C. Baudouin, R. Garraffo, P. Hofmann, A.-M. Taburet, and P. Lapalus: Toxicologic and pharmacokinetic analysis of intravitreal injections of forcarnet, either alone or in combination with ganciclovir. Invest. Ophthalmol. Vis. Sci. 35, 1038-1045 (1994).
23. M. Díaz-Llopis, E. Chipont, S. Sanchez, E. España, A. Navea, and J. L. Menezo: Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am. J. Ophthalmol. 114, 742-747 (1992).